Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Mar;76(3):486-93.

Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area

Egeruan B Imoukhuede  1 , Laura Andrews, Paul Milligan, Tamara Berthoud, Kalifa Bojang, Davis Nwakanma, Jamila Ismaili, Caroline Buckee, Fanta Njie, Saikou Keita, Maimuna Sowe, Trudie Lang, Sarah C Gilbert, Brian M Greenwood, Adrian V S Hill
Affiliations
Randomized Controlled Trial

Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area

Egeruan B Imoukhuede et al. Am J Trop Med Hyg. 2007 Mar.

Abstract

The feasibility of using a sensitive polymerase chain reaction (PCR) to evaluate malaria vaccines in small group sizes was tested in 102 adult Gambian volunteers who received either the malaria vaccine regimen FP9 ME-TRAP/MVA ME-TRAP or rabies vaccine. All volunteers received the antimalarial drugs primaquine and Lapdap plus artesunate to eliminate malaria parasites. Volunteers in a further group received an additional single treatment with sulfadoxine-pyrimethamine (SP) to prevent new infections. There was substantially lower T-cell immunogenicity than in previous trials with this vaccine regimen and no protection against infection in the malaria vaccine group. Using the primary endpoint of 20 parasites per mL, no difference was found in the prevalence of low-level infections in volunteers who received SP compared with those who did not, indicating that SP did not reduce the incidence of very low-density infection. However, SP markedly reduced the incidence of higher density infections. These findings support the feasibility and potential of this approach to screen pre-erythrocytic vaccines for efficacy against infection in small numbers of vaccinees in endemic areas.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Trial profile.
FIGURE 2
FIGURE 2
Ex vivo IFN-γ ELISPOT responses to P. falciparum TRAP vaccination, 7 days after final vaccination in the malaria vaccine (FFM) and the rabies-vaccinated volunteers. PBMC were stimulated with 6 pools of TRAP peptides containing 7–10 20-mer peptides overlapping by 10 amino acids. Median values (gray boxes) and individual values (black spots) are shown.
FIGURE 3
FIGURE 3
Ex vivo IFN-γ ELISPOT responses to P. falciparum TRAP and multi-epitope (ME) peptide pools. Responses are from volunteers in the malaria vaccine (FFM) group 7 days after the final vaccination. Median values (gray boxes) and individual values (black spots) are shown. Significant differences were observed between traps 1 and 2 (P = 0.0058), traps 1 and 5 (P = 0.0058), traps 2 and 4 (P = 0.003), and traps 3 and 4 (P = 0.001). Tests for significance were carried out using the Wilcoxon signed rank test.
FIGURE 4
FIGURE 4
Kaplan-Meier survival estimates showing the probability of remaining free of parasitemia during the 28-day follow-up period: estimates were done using thresholds of (a) 20, (b) 100, and (c) 1000 parasites/mL followed by a second positive PCR result. The population used for efficacy analyses included volunteers who received a full course of malaria or rabies vaccines, excluding volunteers who were PCR-positive on the first day of their surveillance (Group 1 = FFM; Group 2 = rabies + SP; Group 3 = rabies alone). This figure appears in color at www.ajtmh.org.
See this image and copyright information in PMC

References

    1. Hermsen CC, Telgt DS, Linders EH, van de Locht LA, Eling WM, Mensink EJ, Sauerwein RW. Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. Mol Biochem Parasitol. 2001;118:247–251. - PubMed
    1. Bejon P, Andrews L, Andersen RF, Dunachie S, Webster D, Walther M, Gilbert SC, Peto T, Hill AV. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis. 2005;191:619–626. - PubMed
    1. Andrews L, Andersen RF, Webster D, Dunachie S, Walther RM, Bejon P, Hunt-Cooke A, Bergson G, Sanderson F, Hill AV, Gilbert SC. Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. Am J Trop Med Hyg. 2005;73:191–198. - PubMed
    1. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 2001;358:1927–1934. - PubMed
    1. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitie MA, Dubovsky F, Menendez C, Tornieporth N, Ballou WR, Thompson R, Cohen J. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet. 2004;364:1411–1420. - PubMed

Publication types

Substances